Challenges in Infective Endocarditis

Journal of the American College of Cardiology

Volumn 69, Issue 3, 2017, Pages 325-344

  Cahill, Thomas J ^a   Baddour, Larry M ^b   Habib, Gilbert ^c,d   Hoen, Bruno ^e   Salaun, Erwan ^d   Pettersson, Gosta B ^f   Schäfers, Hans Joachim ^g   Prendergast, Bernard D ^h  

^a OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b Mayo Clinic   (United States)

^c AIX MARSEILLE UNIVERSITÉ   (France)

^d TIMONE HOSPITAL   (France)

^e UNIVERSITÉ DES ANTILLES ET DE LA GUYANE   (France)

^f LERNER RESEARCH INSTITUTE   (United States)

^g SAARLAND UNIVERSITY   (Germany)

^h ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

cardiac device infection; infective endocarditis; TAVR

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; ANTIBIOTIC AGENT; CEFTRIAXONE; CIPROFLOXACIN; CLOXACILLIN; DAPTOMYCIN; GENTAMICIN; MONOCLONAL ANTIBODY; OXACILLIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TEICOPLANIN; TRL 1068; UNCLASSIFIED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT;

BACTERIAL ENDOCARDITIS; BIOFILM; CARDIOVASCULAR RISK; CARDIOVASCULAR SURGERY; CEREBROVASCULAR ACCIDENT; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; INCIDENCE; MICROBIOLOGY; MULTICENTER STUDY (TOPIC); NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY-COMPUTED TOMOGRAPHY; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT INDICATION; ADVERSE EFFECTS; AGED; COMPLICATION; DEVICES; ENDOCARDITIS; MALE;

AGED; ANTI-BACTERIAL AGENTS; ENDOCARDITIS; EQUIPMENT AND SUPPLIES; HUMANS; MALE; PRACTICE GUIDELINES AS TOPIC; STROKE;

EID: 85010007206     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2016.10.066     Document Type: Review

References (157)

1. 1 Cahill, T.J., Prendergast, B.D., Infective endocarditis. Lancet 387 (2016), 882–893.
2. 2 Pant, S., Patel, N.J., Deshmukh, A., et al. Trends in infective endocarditis incidence, microbiology, and valve replacement in the United States from 2000 to 2011. J Am Coll Cardiol 65 (2015), 2070–2076.
3. 3 Bor, D.H., Woolhandler, S., Nardin, R., et al. Infective endocarditis in the U.S., 1998–2009: a nationwide study. PLoS One, 8, 2013, e60033.
4. 4 Federspiel, J.J., Stearns, S.C., Peppercorn, A.F., et al. Increasing US rates of endocarditis with Staphylococcus aureus: 1999-2008. Arch Intern Med 172 (2012), 363–365.
5. 5 Dayer, M.J., Jones, S., Prendergast, B., et al. Incidence of infective endocarditis in England, 2000-13: a secular trend, interrupted time-series analysis. Lancet 385 (2015), 1219–1228.
6. 6 Prendergast, B.D., The changing face of infective endocarditis. Heart 92 (2006), 879–885.
7. 7 Seckeler, M.D., Hoke, T.R., The worldwide epidemiology of acute rheumatic fever and rheumatic heart disease. Clin Epidemiol 3 (2011), 67–84.
8. 8 Slipczuk, L., Codolosa, J.N., Davila, C.D., et al. Infective endocarditis epidemiology over five decades: a systematic review. PLoS One, 8, 2013, e82665.
9. 9 Selton-Suty, C., Célard, M., Le Moing, V., et al., AEPEI Study Group. Preeminence of Staphylococcus aureus in infective endocarditis: a 1-year population-based survey. Clin Infect Dis 54 (2012), 1230–1239.
10. 10 Murdoch, D.R., Corey, G., Hoen, B., et al., International Collaboration on Endocarditis-Prospective Cohort Study (ICE-PCS) Investigators. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med 169 (2009), 463–473.
11. 11 Voigt, A., Shalaby, A., Saba, S., Rising rates of cardiac rhythm management device infections in the United States: 1996 through 2003. J Am Coll Cardiol 48 (2006), 590–591.
12. 12 Amat-Santos, I.J., Messika-Zeitoun, D., Eltchaninoff, H., et al. Infective endocarditis after transcatheter aortic valve implantation: results from a large multicenter registry. Circulation 131 (2015), 1566–1574.
13. 13 Mangner, N., Woitek, F., Haussig, S., et al. Incidence, predictors, and outcome of patients developing infective endocarditis following transfemoral transcatheter aortic valve replacement. J Am Coll Cardiol 67 (2016), 2907–2908.
14. 14 Van Dijck, I., Budts, W., Cools, B., et al. Infective endocarditis of a transcatheter pulmonary valve in comparison with surgical implants. Heart 101 (2015), 788–793.
15. 15 Patti, J.M., Allen, B.L., McGavin, M.J., et al. MSCRAMM-mediated adherence of microorganisms to host tissues. Ann Rev Microbiol 48 (1994), 585–617.
16. 16 Werdan, K., Dietz, S., Löffler, B., et al. Mechanisms of infective endocarditis: pathogen-host interaction and risk states. Nat Rev Cardiol 11 (2014), 35–50.
17. 17 Elgharably, H., Hussain, S.T., Shrestha, N.K., et al. Current hypotheses in cardiac surgery: biofilm in infective endocarditis. Semin Thorac Cardiovasc Surg 28 (2016), 56–59.
18. 18 Chung, P.Y., Toh, Y.S., Anti-biofilm agents: recent breakthrough against multi-drug resistant Staphylococcus aureus. Pathog Dis 70 (2014), 231–239.
19. 19 Horder, T.J., Infective endocarditis: with an analysis of 150 cases and with special reference to the chronic form of the disease. Q J Med os2 (1909), 289–324.
20. 20 Okell, C.C., Elliott, S., Bacteraemia and oral sepsis with special reference to the aetiology of subacute endocarditis. Lancet 2 (1935), 869–872.
21. 21 Glaser, R.J., Dankner, A., Mathes, S.B., et al. Effect of penicillin on the bacteremia following dental extraction. Am J Med 4 (1948), 55–65.
22. 22 Hirsh, H.L., Vivino, J.J., Merril, A., et al. Effect of prophylactically administered penicillin on incidence of bacteremia following extraction of teeth; results in patients with healed rheumatic and bacterial endocarditis. Arch Intern Med (Chic) 81 (1948), 868–878.
23. 23 Jones, T.D., Baumgartner, L., Bellows, M.T., et al. Prevention of rheumatic fever and bacterial endocarditis through control of streptococcal infections. Circulation 11 (1955), 317–320.
24. 24 van der Meer, J.T., Michel, M.F., Valkenburg, H.A., et al. Efficacy of antibiotic prophylaxis for prevention of native-valve endocarditis. Lancet 339 (1992), 135–139.
25. 25 van der Meer, J.M., Thompson, J., Valkenburg, H.A., et al. Epidemiology of bacterial endocarditis in the Netherlands. II. antecedent procedures and use of prophylaxis. Arch Intern Med 152 (1992), 1869–1873.
26. 26 Strom, B.L., Abrutyn, E., Berlin, J.A., et al. Dental and cardiac risk factors for infective endocarditis: a population-based, case-control study. Ann Intern Med 129 (1998), 761–769.
27. 27 Lockhart, P.B., Brennan, M.T., Sasser, H.C., et al. Bacteremia associated with toothbrushing and dental extraction. Circulation 117 (2008), 3118–3125.
28. 28 Habib, G., Hoen, B., Tornos, P., et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer. Eur Heart J 30 (2009), 2369–2413.
29. 29 Wilson, W., Taubert, K.A., Gewitz, M., et al. Prevention of infective endocarditis: guidelines from the American Heart Association: guidelines from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 116 (2007), 1736–1754.
30. 30 Chambers, J.B., Shanson, D., Hall, R., et al. Antibiotic prophylaxis of endocarditis: the rest of the world and NICE. J R Soc Med 104 (2011), 138–140.
31. 31 Richey, R., Wray, D., Stokes, T., Prophylaxis against infective endocarditis: summary of NICE guidance. BMJ 336 (2008), 770–771.
32. 32 Danchin, N., Duval, X., Leport, C., Prophylaxis of infective endocarditis: French recommendations 2002. Heart 91 (2005), 715–718.
33. 33 Duval, X., Delahaye, F., Alla, F., et al., AEPEI Study Group. Temporal trends in infective endocarditis in the context of prophylaxis guideline modifications: three successive population-based surveys. J Am Coll Cardiol 59 (2012), 1968–1976.
34. 34 DeSimone, D.C., Tleyjeh, I.M., Correa de Sa, D.D., et al. Incidence of infective endocarditis caused by viridans group streptococci before and after publication of the 2007 American Heart Association's endocarditis prevention guidelines. Circulation 126 (2012), 60–64.
35. 35 DeSimone, D.C., Tleyjeh, I.M., Correa de Sa, D.D., et al., Mayo Cardiovascular Infections Study Group. Incidence of infective endocarditis due to viridans group streptococci before and after the 2007 American Heart Association's prevention guidelines: an extended evaluation of the Olmsted County, Minnesota, population and Nationwide Inpatient Sample. Mayo Clin Proc 90 (2015), 874–881.
36. 36 Mackie, A.S., Liu, W., Savu, A., et al. Infective endocarditis hospitalizations before and after the 2007 American Heart Association prophylaxis guidelines. Can J Cardiol 32 (2016), 942–948.
37. 37 Bikdeli, B., Wang, Y., Kim, N., et al. Trends in hospitalization rates and outcomes of endocarditis among Medicare beneficiaries. J Am Coll Cardiol 62 (2013), 2217–2226.
38. 38 Thornhill, M.H., Dayer, M.J., Forde, J.M., et al. Impact of the NICE guideline recommending cessation of antibiotic prophylaxis for prevention of infective endocarditis: before and after study. BMJ, 342, 2011, d2392.
39. 39 Ruttmann, E., Bonatti, H., Legit, C., et al. Severe endocarditis in transplant recipients—an epidemiologic study. Transplant Int 18 (2005), 690–696.
40. 40 Pulvirenti, J.J., Kerns, E., Benson, C., et al. Infective endocarditis in injection drug users: importance of human immunodeficiency virus serostatus and degree of immunosuppression. Clin Infect Dis 22 (1996), 40–45.
41. 41 Fernández-Hidalgo, N., Almirante, B., Tornos, P., et al. Contemporary epidemiology and prognosis of health care-associated infective endocarditis. Clin Infect Dis 47 (2008), 1287–1297.
42. 42 Chu, V.H., Cabell, C.H., Benjamin, D.K. Jr., et al. Early predictors of in-hospital death in infective endocarditis. Circulation 109 (2004), 1745–1749.
43. 43 Frimodt-Møller, N., Espersen, F., Skinhøj, P., et al. Epidemiology of Staphylococcus aureus bacteremia in Denmark from 1957 to 1990. Clin Microbiol Infect 3 (1997), 297–305.
44. 44 Landrum, M.L., Neumann, C., Cook, C., et al. Epidemiology of Staphylococcus aureus blood and skin and soft tissue infections in the US military health system, 2005-2010. JAMA 308 (2012), 50–59.
45. 45 Tong, S.Y., Davis, J.S., Eichenberger, E., et al. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev 28 (2015), 603–661.
46. 46 Pronovost, P., Needham, D., Berenholtz, S., et al. An intervention to decrease catheter-related bloodstream infections in the ICU. N Engl J Med 355 (2006), 2725–2732.
47. 47 Blot, K., Bergs, J., Vogelaers, D., et al. Prevention of central line-associated bloodstream infections through quality improvement interventions: a systematic review and meta-analysis. Clin Infect Dis 59 (2014), 96–105.
48. 48 CDC. CDC Approach to BSI Prevention in Dialysis Facilities. 2013. Available at: http://www.cdc.gov/dialysis/PDFs/Dialysis-Core-Interventions-5_10_13.pdf. Accessed November 17, 2016.
49. 49 Rhodes, D., Cheng, A.C., McLellan, S., et al. Reducing Staphylococcus aureus bloodstream infections associated with peripheral intravenous cannulae: successful implementation of a care bundle at a large Australian health service. J Hosp Infect 94 (2016), 86–91.
50. 50 Campoccia, D., Montanaro, L., Arciola, C.R., A review of the biomaterials technologies for infection-resistant surfaces. Biomaterials 34 (2013), 8533–8554.
51. 51 Ionescu, A., Payne, N., Fraser, A.G., et al. Incidence of embolism and paravalvar leak after St Jude Silzone valve implantation: experience from the Cardiff Embolic Risk Factor Study. Heart 89 (2003), 1055–1061.
52. 52 Schaff, H.V., Carrel, T.P., Jamieson, W.R., et al. Paravalvular leak and other events in Silzone-coated mechanical heart valves: a report from AVERT. Ann Thorac Surg 73 (2002), 785–792.
53. 53 Shinefield, H., Black, S., Fattom, A., et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med 346 (2002), 491–496.
54. 54 Fowler, V.G. Jr., Allen, K.B., Moreira, E.D., et al. Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial. JAMA 309 (2013), 1368–1378.
55. 55 Bagnoli, F., Fontana, M.R., Soldaini, E., et al. Vaccine composition formulated with a novel TLR7-dependent adjuvant induces high and broad protection against Staphylococcus aureus. Proc Natl Acad Sci 112 (2015), 3680–3685.
56. 56 Dickerman, S.A., Abrutyn, E., Barsic, B., et al., ICE Investigators. The relationship between the initiation of antimicrobial therapy and the incidence of stroke in infective endocarditis: an analysis from the ICE Prospective Cohort Study (ICE-PCS). Am Heart J 154 (2007), 1086–1094.
57. 57 Nihoyannopoulos, P., Oakley, C.M., Exadactylos, N., et al. Duration of symptoms and the effects of a more aggressive surgical policy: two factors affecting prognosis of infective endocarditis. Eur Heart J 6 (1985), 380–390.
58. 58 Lodise, T.P., McKinnon, P.S., Swiderski, L., et al. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis 36 (2003), 1418–1423.
59. 59 Nishimura, R.A., Otto, C.M., Bonow, R.O., et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63 (2014), e57–e185.
60. 60 Pérez-Vázquez, A., Fariñas, M.C., García-Palomo, J.D., et al. Evaluation of the Duke criteria in 93 episodes of prosthetic valve endocarditis: could sensitivity be improved?. Arch Intern Med 160 (2000), 1185–1191.
61. 61 Habib, G., Derumeaux, G., Avierinos, J.F., et al. Value and limitations of the Duke criteria for the diagnosis of infective endocarditis. J Am Coll Cardiol 33 (1999), 2023–2029.
62. 62 Vieira, M.L., Grinberg, M., Pomerantzeff, P.M., et al. Repeated echocardiographic examinations of patients with suspected infective endocarditis. Heart 90 (2004), 1020–1024.
63. 63 Habib, G., Badano, L., Tribouilloy, C., et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and by the International Society of Chemotherapy (ISC) for Infection and Cancer. Eur Heart J 30 (2009), 2369–2413.
64. 64 Habets, J., Tanis, W., Reitsma, J.B., et al. Are novel non-invasive imaging techniques needed in patients with suspected prosthetic heart valve endocarditis? A systematic review and meta-analysis. Eur Radiol 25 (2015), 2125–2133.
65. 65 Fagman, E., Perrotta, S., Bech-Hanssen, O., et al. ECG-gated computed tomography: a new role for patients with suspected aortic prosthetic valve endocarditis. Eur Radiol 22 (2012), 2407–2414.
66. 66 Habets, J., Tanis, W., van Herwerden, L.A., et al. Cardiac computed tomography angiography results in diagnostic and therapeutic change in prosthetic heart valve endocarditis. Int J Cardiovasc Imaging 30 (2014), 377–387.
67. 67 Feuchtner, G.M., Stolzmann, P., Dichtl, W., et al. Multislice computed tomography in infective endocarditis: comparison with transesophageal echocardiography and intraoperative findings. J Am Coll Cardiol 53 (2009), 436–444.
68. 68 Habib, G., Lancellotti, P., Antunes, M.J., et al. 2015 ESC guidelines for the management of infective endocarditis. Eur Heart J 36 (2015), 3075–3128.
69. 69 Saby, L., Laas, O., Habib, G., et al. Positron emission tomography/computed tomography for diagnosis of prosthetic valve endocarditis: increased valvular 18F-fluorodeoxyglucose uptake as a novel major criterion. J Am Coll Cardiol 61 (2013), 2374–2382.
70. 70 Pizzi, M.N., Roque, A., Fernández-Hidalgo, N., et al. Improving the diagnosis of infective endocarditis in prosthetic valves and intracardiac devices with 18F-fluorodeoxyglucose positron emission tomography/computed tomography: initial results at an infective endocarditis referral center. Circulation 132 (2015), 1113–1126.
71. 71 Erba, P.A., Conti, U., Lazzeri, E., et al. Added value of 99mTc-HMPAO-labeled leukocyte SPECT/CT in the characterization and management of patients with infectious endocarditis. J Nucl Med 53 (2012), 1235–1243.
72. 72 Rouzet, F., Chequer, R., Benali, K., et al. Respective performance of 18F-FDG PET and radiolabeled leukocyte scintigraphy for the diagnosis of prosthetic valve endocarditis. J Nucl Med 55 (2014), 1980–1985.
73. 73 Duval, X., Iung, B., Klein, I., et al., Acute Phase of Endocarditis Study Group. Effect of early cerebral magnetic resonance imaging on clinical decisions in infective endocarditis: a prospective study. Ann Intern Med 152 (2010), 497–504.
74. 74 Meshaal, M.S., Kassem, H.H., Samir, A., et al. Impact of routine cerebral CT angiography on treatment decisions in infective endocarditis. PLoS One, 10, 2015, e0118616.
75. 75 Iung, B., Klein, I., Mourvillier, B., et al. Respective effects of early cerebral and abdominal magnetic resonance imaging on clinical decisions in infective endocarditis. Eur Heart J Cardiovasc Imaging 13 (2012), 703–710.
76. 76 Fowler, V.G. Jr., Miro, J.M., Hoen, B., et al., ICE Investigators. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA 293 (2005), 3012–3021.
77. 77 Chirouze, C., Cabell, C.H., Fowler, V.G. Jr., et al., International Collaboration on Endocarditis Study Group. Prognostic factors in 61 cases of Staphylococcus aureus prosthetic valve infective endocarditis from the International Collaboration on Endocarditis Merged Database. Clin Infect Dis 38 (2004), 1323–1327.
78. 78 Wang, A., Athan, E., Pappas, P.A., et al., International Collaboration on Endocarditis-Prospective Cohort Study Investigators. Contemporary clinical profile and outcome of prosthetic valve endocarditis. JAMA 297 (2007), 1354–1361.
79. 79 López, J., Revilla, A., Vilacosta, I., et al. Definition, clinical profile, microbiological spectrum, and prognostic factors of early-onset prosthetic valve endocarditis. Eur Heart J 28 (2007), 760–765.
80. 80 Alonso-Valle, H., Fariñas-Álvarez, C., García-Palomo, J.D., et al. Clinical course and predictors of death in prosthetic valve endocarditis over a 20-year period. J Thorac Cardiovasc Surg 139 (2010), 887–893.
81. 81 Chu, V.H., Woods, C.W., Miro, J.M., et al., International Collaboration on Endocarditis-Prospective Cohort Study Group. Emergence of coagulase-negative staphylococci as a cause of native valve endocarditis. Clin Infect Dis 46 (2008), 232–242.
82. 82 Seng, P., Drancourt, M., Gouriet, F., et al. Ongoing revolution in bacteriology: routine identification of bacteria by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Clin Infect Dis 49 (2009), 543–551.
83. 83 Fournier, P.E., Thuny, F., Richet, H., et al. Comprehensive diagnostic strategy for blood culture-negative endocarditis: a prospective study of 819 new cases. Clin Infect Dis 51 (2010), 131–140.
84. 84 Chambers, J., Sandoe, J., Ray, S., et al. The infective endocarditis team: recommendations from an international working group. Heart 100 (2014), 524–527.
85. 85 Chirillo, F., Scotton, P., Rocco, F., et al. Impact of a multidisciplinary management strategy on the outcome of patients with native valve infective endocarditis. Am J Cardiol 112 (2013), 1171–1176.
86. 86 Botelho-Nevers, E., Thuny, F., Casalta, J.P., et al. Dramatic reduction in infective endocarditis-related mortality with a management-based approach. Arch Intern Med 169 (2009), 1290–1298.
87. 87 Dawson, M., Hunter, T.H., The treatment of subacute bacterial endocarditis with penicillin: results in twenty cases. J Am Med Assoc 127 (1945), 129–137.
88. 88 Loewe, L., Rosenblatt, P., Greene, H.J., et al. Combined penicillin and heparin therapy of subacute bacterial endocarditis: report of seven consecutive successfully treated patients. JAMA 124 (1944), 144–149.
89. 89 Baddour, L.M., Wilson, W.R., Bayer, A.S., et al. American Heart Association Committee on Rheumatic Fever Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and Stroke Council. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications. Circulation 132 (2015), 1435–1486.
90. 90 Francioli, P., Ruch, W., Stamboulian, D., Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone and netilmicin for 14 days: a prospective multicenter study. Clin Infect Dis 21 (1995), 1406–1410.
91. 91 Ribera, E., Gómez-Jimenez, J., Cortes, E., et al. Effectiveness of cloxacillin with and without gentamicin in short-term therapy for right-sided Staphylococcus aureus endocarditis. A randomized, controlled trial. Ann Intern Med 125 (1996), 969–974.
92. 92 Fowler, V.G. Jr., Boucher, H.W., Corey, G.R., et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 355 (2006), 653–665.
93. 93 Cosgrove, S.E., Vigliani, G.A., Campion, M., et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis 48 (2009), 713–721.
94. 94 Fernández-Hidalgo, N., Almirante, B., Gavaldà, J., et al. Ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for treating Enterococcus faecalis infective endocarditis. Clin Infect Dis 56 (2013), 1261–1268.
95. 95 Gavaldà, J., Len, O., Miró, J.M., et al. Brief communication: treatment of Enterococcus faecalis endocarditis with ampicillin plus ceftriaxone. Ann Intern Med 146 (2007), 574–579.
96. 96 Morris, A.J., Drinković, D., Pottumarthy, S., et al. Bacteriological outcome after valve surgery for active infective endocarditis: implications for duration of treatment after surgery. Clin Infect Dis 41 (2005), 187–194.
97. 97 Muñoz, P., Giannella, M., Scoti, F., et al., Group for the Management of Infective Endocarditis of the Gregorio Marañón Hospital (GAME). Two weeks of postsurgical therapy may be enough for high-risk cases of endocarditis caused by Streptococcus viridans or Streptococcus bovis. Clin Microbiol Infect 18 (2012), 293–299.
98. 98 Heldman, A.W., Hartert, T.V., Ray, S.C., et al. Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy. Am J Med 101 (1996), 68–76.
99. 99 Iversen, K., Høst, N., Bruun, N.E., et al. Partial oral treatment of endocarditis. Am Heart J 165 (2013), 116–122.
100. 100 Andrews, M.M., von Reyn, C.F., Patient selection criteria and management guidelines for outpatient parenteral antibiotic therapy for native valve infective endocarditis. Clin Infect Dis 33 (2001), 203–209.
101. 101 Cervera, C., del Río, A., García, L., et al., Hospital Clinic Endocarditis Study Group. Efficacy and safety of outpatient parenteral antibiotic therapy for infective endocarditis: a ten-year prospective study. Enfermedades Infecciosas y Microbiología Clínica 29 (2011), 587–592.
102. 102 Duncan, C.J., Barr, D.A., Ho, A., et al. Risk factors for failure of outpatient parenteral antibiotic therapy (OPAT) in infective endocarditis. J Antimicrob Chemother 68 (2013), 1650–1654.
103. 103 Lewis, K., Platforms for antibiotic discovery. Nat Rev Drug Discovery 12 (2013), 371–387.
104. 104 Estellés, A., Woischnig, A.K., Liu, K., et al. A high-affinity native human antibody disrupts biofilm from Staphylococcus aureus bacteria and potentiates antibiotic efficacy in a mouse implant infection model. Antimicrob Agents Chemother 60 (2016), 2292–2301.
105. 105 Musci, M., Weng, Y., Hübler, M., et al. Homograft aortic root replacement in native or prosthetic active infective endocarditis: twenty-year single-center experience. Thorac Cardiovasc Surg 139 (2010), 665–673.
106. 106 Manne, M.B., Shrestha, N.K., Lytle, B.W., et al. Outcomes after surgical treatment of native and prosthetic valve infective endocarditis. Ann Thorac Surg 93 (2012), 489–493.
107. 107 Prendergast, B.D., Tornos, P., Surgery for infective endocarditis: who and when?. Circulation 121 (2010), 1141–1152.
108. 108 Chu, V.H., Park, L.P., Athan, E., et al., International Collaboration on Endocarditis Investigators. Association between surgical indications, operative risk and clinical outcome in infective endocarditis: a prospective study from the International Collaboration on Endocarditis. Circulation 131 (2015), 131–140.
109. 109 San Román, J.A., Vilacosta, I., López, J., et al. Critical questions about left-sided infective endocarditis. J Am Coll Cardiol 66 (2015), 1068–1076.
110. 110 Gaca, J.G., Sheng, S., Daneshmand, M.A., et al. Outcomes for endocarditis surgery in North America: a simplified risk scoring system. J Thorac Cardiovasc Surg 141 (2011), 98–106.e1–2.
111. 111 De Feo, M., Cotrufo, M., Carozza, A., et al. The need for a specific risk prediction system in native valve infective endocarditis surgery. Scientific World Journal, 2012, 2012, 307571.
112. 112 Martínez-Sellés, M., Muñoz, P., Arnáiz, A., et al., Spanish Collaboration on Endocarditis-Grupo de Apoyo al Manejo de la Endocarditis infecciosa en ESpaña (GAMES). Valve surgery in active infective endocarditis: a simple score to predict in-hospital prognosis. Int J Cardiol 175 (2014), 133–137.
113. 113 Lalani, T., Chu, V.H., Park, L.P., et al., International Collaboration on Endocarditis-Prospective Cohort Study Investigators. In-hospital and 1-year mortality in patients undergoing early surgery for prosthetic valve endocarditis. JAMA Intern Med 173 (2013), 1495–1504.
114. 114 Lalani, T., Cabell, C.H., Benjamin, D.K., et al. Analysis of the impact of early surgery on in-hospital mortality of native valve endocarditis. Circulation 121 (2010), 1005–1013.
115. 115 Chirouze, C., Alla, F., Fowler, V.G. Jr., et al., ICE Prospective Investigators. Impact of early valve surgery on outcome of Staphylococcus aureus prosthetic valve infective endocarditis: analysis in the International Collaboration of Endocarditis-Prospective Cohort Study. Clin Infect Dis 60 (2015), 741–749.
116. 116 Hussain ST, Shrestha NK, Gordon SM, et al. Residual patient, anatomic, and surgical obstacles in treating active left-sided infective endocarditis. J Thorac Cardiovasc Surg 2014;148:981–8.e4.
117. 117 Leon, M.B., Smith, C.R., Mack, M., et al., PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 363 (2010), 1597–1607.
118. 118 Smith, C.R., Leon, M.B., Mack, M.J., et al., PARTNER Trial Investigators. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 364 (2011), 2187–2198.
119. 119 Regueiro, A., Linke, A., Latib, A., et al. Association between transcatheter aortic valve replacement and subsequent infective endocarditis and in-hospital death. JAMA 316 (2016), 1083–1092.
120. 120 Thuny, F., Avierinos, J.F., Tribouilloy, C., et al. Impact of cerebrovascular complications on mortality and neurologic outcome during infective endocarditis: a prospective multicentre study. Eur Heart J 28 (2007), 1155–1161.
121. 121 Barsic, B., Dickerman, S., Krajinovic, V., et al., International Collaboration on Endocarditis-Prospective Cohort Study (ICE-PCS) Investigators. Influence of the timing of cardiac surgery on the outcome of patients with infective endocarditis and stroke. Clin Infect Dis 56 (2013), 209–217.
122. 122 Hasbun, R., Vikram, H.R., Barakat, L.A., et al. Complicated left-sided native valve endocarditis in adults: risk classification for mortality. JAMA 289 (2003), 1933–1940.
123. 123 Vilacosta, I., Graupner, C., San Román, J.A., et al. Risk of embolization after institution of antibiotic therapy for infective endocarditis. J Am Coll Cardiol 39 (2002), 1489–1495.
124. 124 Thuny, F., Di Salvo, G., Belliard, O., et al. Risk of embolism and death in infective endocarditis: prognostic value of echocardiography: a prospective multicenter study. Circulation 112 (2005), 69–75.
125. 125 García-Cabrera, E., Fernández-Hidalgo, N., Almirante, B., et al. Group for the Study of Cardiovascular Infections of the Andalusian Society of Infectious Diseases (SAEI), Spanish Network for Research in Infectious Diseases (REIPI). Neurological complications of infective endocarditis: risk factors, outcome, and impact of cardiac surgery: a multicenter observational study. Circulation 127 (2013), 2272–2284.
126. 126 Kang, D.H., Kim, Y.J., Kim, S.H., et al. Early surgery versus conventional treatment for infective endocarditis. N Engl J Med 366 (2012), 2466–2473.
127. 127 Ruttmann, E., Willeit, J., Ulmer, H., et al. Neurological outcome of septic cardioembolic stroke after infective endocarditis. Stroke 37 (2006), 2094–2099.
128. 128 Voigt, A., Shalaby, A., Saba, S., Continued rise in rates of cardiovascular implantable electronic device infections in the United States: temporal trends and causative insights. Pacing Clin Electrophysiol 33 (2010), 414–419.
129. 129 Uslan, D.Z., Sohail, M.R., St. Sauver, J.L., et al. Permanent pacemaker and implantable cardioverter defibrillator infection: a population-based study. Arch Intern Med 167 (2007), 669–675.
130. 130 Johansen, J.B., Jørgensen, O.D., Møller, M., et al. Infection after pacemaker implantation: infection rates and risk factors associated with infection in a population-based cohort study of 46299 consecutive patients. Eur Heart J 32 (2011), 991–998.
131. 131 Landolina, M., Gasparini, M., Lunati, M., et al. Long-term complications related to biventricular defibrillator implantation: rate of surgical revisions and impact on survival: insights from the Italian Clinical Service Database. Circulation 123 (2011), 2526–2535.
132. 132 Rizwan Sohail, M., Henrikson, C.A., Braid-Forbes, M., et al. Increased long-term mortality in patients with cardiovascular implantable electronic device infections. Pacing Clin Electrophysiol 38 (2015), 231–239.
133. 133 Sohail, M.R., Henrikson, C.A., Braid-Forbes, M.J., et al. Mortality and cost associated with cardiovascular implantable electronic device infections. Arch Intern Med 171 (2011), 1821–1828.
134. 134 Bongiorni, M.G., Tascini, C., Tagliaferri, E., et al. Microbiology of cardiac implantable electronic device infections. Europace 14 (2012), 1334–1339.
135. 135 Polyzos, K.A., Konstantelias, A.A., Falagas, M.E., Risk factors for cardiac implantable electronic device infection: a systematic review and meta-analysis. Europace 17 (2015), 767–777.
136. 136 Da Costa, A., Kirkorian, G., Cucherat, M., et al. Antibiotic prophylaxis for permanent pacemaker implantation: a meta-analysis. Circulation 97 (1998), 1796–1801.
137. 137 Victor, F., De Place, C., Camus, C., et al. Pacemaker lead infection: echocardiographic features, management, and outcome. Heart 81 (1999), 82–87.
138. 138 Downey, B.C., Juselius, W.E., Pandian, N.G., et al. Incidence and significance of pacemaker and implantable cardioverter-defibrillator lead masses discovered during transesophageal echocardiography. Pacing Clin Electrophysiol 34 (2011), 679–683.
139. 139 Sarrazin, J.F., Philippon, F., Tessier, M., et al. Usefulness of fluorine-18 positron emission tomography/computed tomography for identification of cardiovascular implantable electronic device infections. J Am Coll Cardiol 59 (2012), 1616–1625.
140. 140 Ahmed, F.Z., James, J., Cunnington, C., et al. Early diagnosis of cardiac implantable electronic device generator pocket infection using 18F-FDG-PET/CT. Eur Heart J Cardiovasc Imaging 16 (2015), 521–530.
141. 141 Cautela, J., Alessandrini, S., Cammilleri, S., et al. Diagnostic yield of FDG positron-emission tomography/computed tomography in patients with CEID infection: a pilot study. Europace 15 (2013), 252–257.
142. 142 Sandoe, J.A., Barlow, G., Chambers, J.B., et al. Guidelines for the diagnosis, prevention and management of implantable cardiac electronic device infection. Report of a joint Working Party project on behalf of the British Society for Antimicrobial Chemotherapy (BSAC, host organization), British Heart Rhythm Society (BHRS), British Cardiovascular Society (BCS), British Heart Valve Society (BHVS) and British Society for Echocardiography (BSE). J Antimicrob Chemother 70 (2015), 325–359.
143. 143 Baddour, L.M., Epstein, A.E., Erickson, C.C., et al. Council on Cardiovascular Surgery and Anesthesia Council on Cardiovascular Nursing Council on Clinical Cardiology, Interdisciplinary Council on Quality of Care and Outcomes Research. Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association. Circulation 121 (2010), 458–477.
144. 144 Fu, H.X., Huang, X.M., Zhong, L.I., et al. Outcomes and complications of lead removal: can we establish a risk stratification schema for a collaborative and effective approach?. Pacing Clin Electrophysiol 38 (2015), 1439–1447.
145. 145 Regitz-Zagrosek, V., Blomstrom Lundqvist, C., Borghi, C., et al. ESC guidelines on the management of cardiovascular diseases during pregnancy. Eur Heart J 32 (2011), 3147–3197.
146. 146 Warnes, C.A., Williams, R.G., Bashore, T.M., et al. ACC/AHA 2008 guidelines for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Management of Adults With Congenital Heart Disease) developed in collaboration with the American Society of Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 52 (2008), e143–e263.
147. 147 Chan, K.L., Dumesnil, J.G., Cujec, B., et al., Investigators of the Multicenter Aspirin Study in Infective Endocarditis. A randomized trial of aspirin on the risk of embolic events in patients with infective endocarditis. J Am Coll Cardiol 42 (2003), 775–780.
148. 148 Fortún, J., Navas, E., Martínez-Beltrán, J., et al. Short-course therapy for right-side endocarditis due to Staphylococcus aureus in drug abusers: cloxacillin versus glycopeptides in combination with gentamicin. Clin Infect Dis 33 (2001), 120–125.
149. 149 Sexton, D.J., Tenenbaum, M.J., Wilson, W.R., et al. Ceftriaxone once daily for four weeks compared with ceftriaxone plus gentamicin once daily for two weeks for treatment of endocarditis due to penicillin-susceptible streptococci. Endocarditis Treatment Consortium Group. Clin Infect Dis 27 (1998), 1470–1474.
150. 150 Aung, T., Poon, K., Horvath, R., et al. A case series of medically managed infective endocarditis after transcatheter aortic valve replacement. Scand J Infect Dis 45 (2013), 489–493.
151. 151 Bosmans, J.M., Kefer, J., De Bruyne, B., et al., Belgian TAVI Registry Participants. Procedural, 30-day and one year outcome following CoreValve or Edwards transcatheter aortic valve implantation: results of the Belgian national registry. Interactive CardioVasc Thorac Surg 12 (2011), 762–767.
152. 152 Latib, A., Naim, C., De Bonis, M., et al. TAVR-associated prosthetic valve infective endocarditis: results of a large, multicenter registry. J Am Coll Cardiol 64 (2014), 2176–2178.
153. 153 Olsen, N.T., De Backer, O., Thyregod, H.G., et al. Prosthetic valve endocarditis after transcatheter aortic valve implantation. Circ Cardiovasc Interv, 8, 2015, e001939.
154. 154 Puls, M., Eiffert, H., Hünlich, M., et al. Prosthetic valve endocarditis after transcatheter aortic valve implantation: the incidence in a single-centre cohort and reflections on clinical, echocardiographic and prognostic features. EuroIntervention 8 (2013), 1407–1418.
155. 155 Thomas, M., Schymik, G., Walther, T., et al. One-year outcomes of Cohort 1 in the Edwards SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) Registry. Circulation 124 (2011), 425–433.
156. 156 Keller, K., von Bardeleben, R.S., Ostad, M.A., et al. Temporal trends in the prevalence of infective endocarditis in Germany between 2005 and 2014. J Am Coll Cardiol, 2016 [E-pub ahead of print].
157. 157 van den Brink, F.S., Swaans, M.J., Hoogendijk, M.G., et al. Increased incidence of infective endocarditis after the 2009 European Society of Cardiology Guideline Update: A nation-wide study in the Netherlands. European Heart Journal - Quality of Care and Clinical Outcomes, 2016 [E-pub ahead of print].